Granulocyte Colony-Stimulating Factor Receptor Signaling. Implications for G-CSF Responses and Leukemic Progression in Severe Congenital Neutropenia.

Hematology/Oncology Clinics of North America

Volumn 27, Issue 1, 2013, Pages 61-73

  Touw, Ivo P ^a   Palande, Karishma ^b   Beekman, Renée ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

G CSF; G CSF receptor; Leukemia; Severe congenital neutropenia; Signal transduction

Indexed keywords

BORTEZOMIB; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE COLONY STIMULATING FACTOR RECEPTOR; LEUKOCYTE ELASTASE; PROTEIN TYROSINE PHOSPHATASE 1B; REACTIVE OXYGEN METABOLITE; STAT5 PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; CANCER GROWTH; GENE MUTATION; HUMAN; INTRACELLULAR SIGNALING; LEUKEMIA; MYELODYSPLASTIC SYNDROME; NONHUMAN; NOONAN SYNDROME; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROTEIN DEFECT; PROTEIN FUNCTION; PROTEIN MODIFICATION; REVIEW; SEVERE CONGENITAL NEUTROPENIA; UBIQUITINATION;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; DISEASE PROGRESSION; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; LEUKEMIA; LYSOSOMES; MUTATION; NEUTROPENIA; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 1; REACTIVE OXYGEN SPECIES; RECEPTORS, GRANULOCYTE COLONY-STIMULATING FACTOR; SIGNAL TRANSDUCTION; UBIQUITINATION;

EID: 84872715743     PISSN: 08898588     EISSN: 15581977     Source Type: Journal    
DOI: 10.1016/j.hoc.2012.10.002     Document Type: Review

References (85)

1. Demetri G.D., Griffin J.D. Granulocyte colony-stimulating factor and its receptor. Blood 1991, 78(11):2791-2808.
2. Lieschke G.J. CSF-deficient mice-what have they taught us?. Ciba Found Symp 1997, 204:60-74. [discussion: 7].
3. Lieschke G.J., Grail D., Hodgson G., et al. Mice lacking granulocyte colony-stimulating factor have chronic neutropenia, granulocyte and macrophage progenitor cell deficiency, and impaired neutrophil mobilization. Blood 1994, 84(6):1737-1746.
4. Liu F., Wu H.Y., Wesselschmidt R., et al. Impaired production and increased apoptosis of neutrophils in granulocyte colony-stimulating factor receptor-deficient mice. Immunity 1996, 5(5):491-501.
5. Bazan J.F. Structural design and molecular evolution of a cytokine receptor superfamily. Proc Natl Acad Sci U S A 1990, 87(18):6934-6938.
6. Layton J.E., Hall N.E. The interaction of G-CSF with its receptor. Front Biosci 2006, 11:3181-3189.
7. Touw I.P., van de Geijn G.J. Granulocyte colony-stimulating factor and its receptor in normal myeloid cell development, leukemia and related blood cell disorders. Front Biosci 2007, 12:800-815.
8. Skokowa J., Cario G., Uenalan M., et al. LEF-1 is crucial for neutrophil granulocytopoiesis and its expression is severely reduced in congenital neutropenia. Nat Med 2006, 12(10):1191-1197.
9. Skokowa J., Lan D., Thakur B.K., et al. NAMPT is essential for the G-CSF-induced myeloid differentiation via a NAD(+)-sirtuin-1-dependent pathway. Nat Med 2009, 15(2):151-158.
10. Hermans M.H., Antonissen C., Ward A.C., et al. Sustained receptor activation and hyperproliferation in response to granulocyte colony-stimulating factor (G-CSF) in mice with a severe congenital neutropenia/acute myeloid leukemia-derived mutation in the G-CSF receptor gene. J Exp Med 1999, 189(4):683-692.
11. Lee C.K., Raz R., Gimeno R., et al. STAT3 is a negative regulator of granulopoiesis but is not required for G-CSF-dependent differentiation. Immunity 2002, 17(1):63-72.
12. Ward A.C., Smith L., de Koning J.P., et al. Multiple signals mediate proliferation, differentiation, and survival from the granulocyte colony-stimulating factor receptor in myeloid 32D cells. J Biol Chem 1999, 274(21):14956-14962.
13. Hermans M.H., van de Geijn G.J., Antonissen C., et al. Signaling mechanisms coupled to tyrosines in the granulocyte colony-stimulating factor receptor orchestrate G-CSF-induced expansion of myeloid progenitor cells. Blood 2003, 101(7):2584-2590.
14. Hortner M., Nielsch U., Mayr L.M., et al. Suppressor of cytokine signaling-3 is recruited to the activated granulocyte-colony stimulating factor receptor and modulates its signal transduction. J Immunol 2002, 169(3):1219-1227.
15. de Koning J.P., Schelen A.M., Dong F., et al. Specific involvement of tyrosine 764 of human granulocyte colony-stimulating factor receptor in signal transduction mediated by p145/Shc/GRB2 or p90/GRB2 complexes. Blood 1996, 87(1):132-140.
16. de Koning J.P., Soede-Bobok A.A., Schelen A.M., et al. Proliferation signaling and activation of Shc, p21Ras, and Myc via tyrosine 764 of human granulocyte colony-stimulating factor receptor. Blood 1998, 91(6):1924-1933.
17. Ward A.C. The role of the granulocyte colony-stimulating factor receptor (G-CSF-R) in disease. Front Biosci 2007, 12:608-618.
18. de Bruin A.M., Libregts S.F., Valkhof M., et al. IFNgamma induces monopoiesis and inhibits neutrophil development during inflammation. Blood 2012, 119(6):1543-1554.
19. Dale D.C., Link D.C. The many causes of severe congenital neutropenia. N Engl J Med 2009, 360(1):3-5.
20. Klein C. Congenital neutropenia. Hematology Am Soc Hematol Educ Program 2009, 344-350.
21. Horwitz M.S., Duan Z., Korkmaz B., et al. Neutrophil elastase in cyclic and severe congenital neutropenia. Blood 2007, 109(5):1817-1824.
22. Klein C., Grudzien M., Appaswamy G., et al. HAX1 deficiency causes autosomal recessive severe congenital neutropenia (Kostmann disease). Nat Genet 2007, 39(1):86-92.
23. Freedman M.H., Alter B.P. Risk of myelodysplastic syndrome and acute myeloid leukemia in congenital neutropenias. Semin Hematol 2002, 39(2):128-133.
24. Freedman M.H., Bonilla M.A., Fier C., et al. Myelodysplasia syndrome and acute myeloid leukemia in patients with congenital neutropenia receiving G-CSF therapy. Blood 2000, 96(2):429-436.
25. Dale D.C., Bonilla M.A., Davis M.W., et al. A randomized controlled phase III trial of recombinant human granulocyte colony-stimulating factor (filgrastim) for treatment of severe chronic neutropenia. Blood 1993, 81(10):2496-2502.
26. Dale D.C., Cottle T.E., Fier C.J., et al. Severe chronic neutropenia: treatment and follow-up of patients in the Severe Chronic Neutropenia International Registry. Am J Hematol 2003, 72(2):82-93.
27. Rosenberg P.S., Alter B.P., Bolyard A.A., et al. The incidence of leukemia and mortality from sepsis in patients with severe congenital neutropenia receiving long-term G-CSF therapy. Blood 2006, 107(12):4628-4635.
28. Zeidler C., Germeshausen M., Klein C., et al. Clinical implications of ELA2-, HAX1-, and G-CSF-receptor (CSF3R) mutations in severe congenital neutropenia. Br J Haematol 2009, 144(4):459-467.
29. Dong F., Brynes R.K., Tidow N., et al. Mutations in the gene for the granulocyte colony-stimulating-factor receptor in patients with acute myeloid leukemia preceded by severe congenital neutropenia. N Engl J Med 1995, 333(8):487-493.
30. Dong F., Hoefsloot L.H., Schelen A.M., et al. Identification of a nonsense mutation in the granulocyte-colony-stimulating factor receptor in severe congenital neutropenia. Proc Natl Acad Sci U S A 1994, 91(10):4480-4484.
31. Dong F., Dale D.C., Bonilla M.A., et al. Mutations in the granulocyte colony-stimulating factor receptor gene in patients with severe congenital neutropenia. Leukemia 1997, 11(1):120-125.
32. Tidow N., Pilz C., Teichmann B., et al. Clinical relevance of point mutations in the cytoplasmic domain of the granulocyte colony-stimulating factor receptor gene in patients with severe congenital neutropenia. Blood 1997, 89(7):2369-2375.
33. Dong F., van Buitenen C., Pouwels K., et al. Distinct cytoplasmic regions of the human granulocyte colony-stimulating factor receptor involved in induction of proliferation and maturation. Mol Cell Biol 1993, 13(12):7774-7781.
34. Fukunaga R., Ishizaka-Ikeda E., Nagata S. Growth and differentiation signals mediated by different regions in the cytoplasmic domain of granulocyte colony-stimulating factor receptor. Cell 1993, 74(6):1079-1087.
35. Hermans M.H., Ward A.C., Antonissen C., et al. Perturbed granulopoiesis in mice with a targeted mutation in the granulocyte colony-stimulating factor receptor gene associated with severe chronic neutropenia. Blood 1998, 92(1):32-39.
36. McLemore M.L., Poursine-Laurent J., Link D.C. Increased granulocyte colony-stimulating factor responsiveness but normal resting granulopoiesis in mice carrying a targeted granulocyte colony-stimulating factor receptor mutation derived from a patient with severe congenital neutropenia. J Clin Invest 1998, 102(3):483-492.
37. Zhu Q.S., Xia L., Mills G.B., et al. G-CSF induced reactive oxygen species involves Lyn-PI3-kinase-Akt and contributes to myeloid cell growth. Blood 2006, 107(5):1847-1856.
38. Liu F., Kunter G., Krem M.M., et al. Csf3r mutations in mice confer a strong clonal HSC advantage via activation of Stat5. J Clin Invest 2008, 118(3):946-955.
39. Aarts L.H., Roovers O., Ward A.C., et al. Receptor activation and 2 distinct COOH-terminal motifs control G-CSF receptor distribution and internalization kinetics. Blood 2004, 103(2):571-579.
40. Ward A.C., van Aesch Y.M., Schelen A.M., et al. Defective internalization and sustained activation of truncated granulocyte colony-stimulating factor receptor found in severe congenital neutropenia/acute myeloid leukemia. Blood 1999, 93(2):447-458.
41. Sorkin A., von Zastrow M. Endocytosis and signalling: intertwining molecular networks. Nat Rev Mol Cell Biol 2009, 10(9):609-622.
42. Polo S., Di Fiore P.P. Endocytosis conducts the cell signaling orchestra. Cell 2006, 124(5):897-900.
43. Scita G., Di Fiore P.P. The endocytic matrix. Nature 2010, 463(7280):464-473.
44. Zwang Y., Yarden Y. Systems biology of growth factor-induced receptor endocytosis. Traffic 2009, 10(4):349-363.
45. Irandoust M.I., Aarts L.H., Roovers O., et al. Suppressor of cytokine signaling 3 controls lysosomal routing of G-CSF receptor. EMBO J 2007, 26(7):1782-1793.
46. Wolfler A., Irandoust M., Meenhuis A., et al. Site-specific ubiquitination determines lysosomal sorting and signal attenuation of the granulocyte colony-stimulating factor receptor. Traffic 2009, 10(8):1168-1179.
47. Levkowitz G., Waterman H., Zamir E., et al. c-Cbl/Sli-1 regulates endocytic sorting and ubiquitination of the epidermal growth factor receptor. Genes Dev 1998, 12(23):3663-3674.
48. Umebayashi K., Stenmark H., Yoshimori T. Ubc4/5 and c-Cbl continue to ubiquitinate EGF receptor after internalization to facilitate polyubiquitination and degradation. Mol Biol Cell 2008, 19(8):3454-3462.
49. Gesbert F., Malarde V., Dautry-Varsat A. Ubiquitination of the common cytokine receptor gammac and regulation of expression by an ubiquitination/deubiquitination machinery. Biochem Biophys Res Commun 2005, 334(2):474-480.
50. Saur S.J., Sangkhae V., Geddis A.E., et al. Ubiquitination and degradation of the thrombopoietin receptor c-Mpl. Blood 2010, 115(6):1254-1263.
51. Tanaka Y., Tanaka N., Saeki Y., et al. c-Cbl-dependent monoubiquitination and lysosomal degradation of gp130. Mol Cell Biol 2008, 28(15):4805-4818.
52. Meyer L., Deau B., Forejtnikova H., et al. beta-Trcp mediates ubiquitination and degradation of the erythropoietin receptor and controls cell proliferation. Blood 2007, 109(12):5215-5222.
53. Friedman A.D., Nimbalkar D., Quelle F.W. Erythropoietin receptors associate with a ubiquitin ligase, p33RUL, and require its activity for erythropoietin-induced proliferation. J Biol Chem 2003, 278(29):26851-26861.
54. Fujimoto M., Naka T. Regulation of cytokine signaling by SOCS family molecules. Trends Immunol 2003, 24(12):659-666.
55. Kile B.T., Schulman B.A., Alexander W.S., et al. The SOCS box: a tale of destruction and degradation. Trends Biochem Sci 2002, 27(5):235-241.
56. Sasaki A., Yasukawa H., Suzuki A., et al. Cytokine-inducible SH2 protein-3 (CIS3/SOCS3) inhibits Janus tyrosine kinase by binding through the N-terminal kinase inhibitory region as well as SH2 domain. Genes Cells 1999, 4(6):339-351.
57. Yoshimura A., Naka T., Kubo M. SOCS proteins, cytokine signalling and immune regulation. Nat Rev Immunol 2007, 7(6):454-465.
58. Kamura T., Maenaka K., Kotoshiba S., et al. VHL-box and SOCS-box domains determine binding specificity for Cul2-Rbx1 and Cul5-Rbx2 modules of ubiquitin ligases. Genes Dev 2004, 18(24):3055-3065.
59. Boyle K., Egan P., Rakar S., et al. The SOCS box of suppressor of cytokine signaling-3 contributes to the control of G-CSF responsiveness in vivo. Blood 2007, 110(5):1466-1474.
60. van de Geijn G.J., Gits J., Touw I.P. Distinct activities of suppressor of cytokine signaling (SOCS) proteins and involvement of the SOCS box in controlling G-CSF signaling. J Leukoc Biol 2004, 76(1):237-244.
61. Baek K.H., Kim M.S., Kim Y.S., et al. DUB-1A, a novel deubiquitinating enzyme subfamily member, is polyubiquitinated and cytokine-inducible in B-lymphocytes. J Biol Chem 2004, 279(4):2368-2376.
62. Baek K.H., Mondoux M.A., Jaster R., et al. DUB-2A, a new member of the DUB subfamily of hematopoietic deubiquitinating enzymes. Blood 2001, 98(3):636-642.
63. Zhu Y., Lambert K., Corless C., et al. DUB-2 is a member of a novel family of cytokine-inducible deubiquitinating enzymes. J Biol Chem 1997, 272(1):51-57.
64. Zhu Y., Pless M., Inhorn R., et al. The murine DUB-1 gene is specifically induced by the betac subunit of interleukin-3 receptor. Mol Cell Biol 1996, 16(9):4808-4817.
65. Meenhuis A., Verwijmeren C., Roovers O., et al. The deubiquitinating enzyme DUB2A enhances CSF3 signalling by attenuating lysosomal routing of the CSF3 receptor. Biochem J 2011, 434(2):343-351.
66. Meenhuis A., Irandoust M., Wolfler A., et al. Janus kinases promote cell-surface expression and provoke autonomous signalling from routing-defective G-CSF receptors. Biochem J 2009, 417(3):737-746.
67. Beel K., Vandenberghe P. G-CSF receptor (CSF3R) mutations in X-linked neutropenia evolving to acute myeloid leukemia or myelodysplasia. Haematologica 2009, 94(10):1449-1452.
68. Uruno T., Zhang P., Liu J., et al. Haematopoietic lineage cell-specific protein 1 (HS1) promotes actin-related protein (Arp) 2/3 complex-mediated actin polymerization. Biochem J 2003, 371(Pt 2):485-493.
69. Tapley P., Shevde N.K., Schweitzer P.A., et al. Increased G-CSF responsiveness of bone marrow cells from hematopoietic cell phosphatase deficient viable motheaten mice. Exp Hematol 1997, 25(2):122-131.
70. Dance M., Montagner A., Salles J.P., et al. The molecular functions of Shp2 in the Ras/Mitogen-activated protein kinase (ERK1/2) pathway. Cell Signal 2008, 20(3):453-459.
71. Neel B.G., Gu H., Pao L. The 'Shp'ing news: SH2 domain-containing tyrosine phosphatases in cell signaling. Trends Biochem Sci 2003, 28(6):284-293.
72. Palande K., Roovers O., Gits J., et al. Peroxiredoxin-controlled G-CSF signalling at the endoplasmic reticulum-early endosome interface. J Cell Sci 2011, 124(Pt 21):3695-3705.
73. Stuible M., Tremblay M.L. In control at the ER: PTP1B and the down-regulation of RTKs by dephosphorylation and endocytosis. Trends Cell Biol 2010, 20:672-679.
74. Frangioni J.V., Beahm P.H., Shifrin V., et al. The nontransmembrane tyrosine phosphatase PTP-1B localizes to the endoplasmic reticulum via its 35 amino acid C-terminal sequence. Cell 1992, 68(3):545-560.
75. Bedard K., Krause K.H. The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol Rev 2007, 87(1):245-313.
76. Chen K., Kirber M.T., Xiao H., et al. Regulation of ROS signal transduction by NADPH oxidase 4 localization. J Cell Biol 2008, 181(7):1129-1139.
77. Mahadev K., Zilbering A., Zhu L., et al. Insulin-stimulated hydrogen peroxide reversibly inhibits protein-tyrosine phosphatase 1b in vivo and enhances the early insulin action cascade. J Biol Chem 2001, 276(4):21938-21942.
78. Meng T.C., Buckley D.A., Galic S., et al. Regulation of insulin signaling through reversible oxidation of the protein-tyrosine phosphatases TC45 and PTP1B. J Biol Chem 2004, 279(36):37716-37725.
79. Rhee S.G., Woo H.A., Kil I.S., et al. Peroxiredoxin functions as a peroxidase and a regulator and sensor of local peroxides. J Biol Chem 2012, 287(7):4403-4410.
80. Choi M.H., Lee I.K., Kim G.W., et al. Regulation of PDGF signalling and vascular remodelling by peroxiredoxin II. Nature 2005, 435(7040):347-353.
81. Woo H.A., Yim S.H., Shin D.H., et al. Inactivation of peroxiredoxin I by phosphorylation allows localized H(2)O(2) accumulation for cell signaling. Cell 2010, 140(4):517-528.
82. Tavender T.J., Sheppard A.M., Bulleid N.J. Peroxiredoxin IV is an endoplasmic reticulum-localized enzyme forming oligomeric complexes in human cells. Biochem J 2008, 411(1):191-199.
83. Palande K.K., Beekman R., van der Meeren L.E., et al. The antioxidant protein peroxiredoxin 4 is epigenetically down regulated in acute promyelocytic leukemia. PLoS One 2011, 6(1):e16340.
84. Germeshausen M., Ballmaier M., Welte K. Incidence of CSF3R mutations in severe congenital neutropenia and relevance for leukemogenesis: results of a long-term survey. Blood 2007, 109(1):93-99.
85. Beekman R., Valkhof M.G., Sanders M.A., et al. Sequential gain of mutations in severe congenital neutropenia progressing to acute myeloid leukemia. Blood 2012, 119(22):5071-5077.